



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

Medicare Carrier Part B	CPT Code HCPCS Code	Units	Diagnosis Coverage	Instructions
<p>Cahaba GBA www.cahabagba.com Alabama, Georgia, Tennessee,</p> <p>L34252</p>	<p>67028 J2778</p>	<p>3 or 5</p>	<p>E08.311 Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema E08.321 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema E08.331 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema E08.341 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema E08.351 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema E09.311 Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema E09.321 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy</p>	<p>Indications: FDA: A. Neovascular (wet) age-related macular degeneration. B. Macular edema following retinal vein occlusion (RVO). C. Diabetic macular edema</p> <p>Utilization Guidelines: For labeled indications, the dose and frequency of administration should be consistent with the FDA approved package insert.</p>



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

			<p>with macular edema</p> <p>E09.331 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E09.341 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E09.351 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E10.311 Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema</p> <p>E10.321 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E10.331 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E10.341 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E10.351 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with</p>	
--	--	--	---	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>macular edema</p> <p>E11.321 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E11.331 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E11.341 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E11.351 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E13.311 Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema</p> <p>E13.321 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E13.331 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E13.341 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E13.351 Other specified diabetes mellitus with proliferative diabetic</p>	
--	--	--	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

			<p>retinopathy with macular edema H34.811 - H34.813- Opens in a new window Central retinal vein occlusion, right eye - Central retinal vein occlusion, bilateral H34.831 - H34.833- Opens in a new window Tributary (branch) retinal vein occlusion, right eye - Tributary (branch) retinal vein occlusion, bilateral H35.32 Exudative age-related macular degeneration</p>	
<p>First Coast Service Options http://medicare.fcso.com Florida, Puerto Rico L33407</p>	<p>67028 J2778</p>	<p>3 or 5</p>	<p>E08.321 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema E08.331 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema E08.341 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema E08.351 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema E09.311 Drug or chemical induced</p>	<p>Documentation Requirements Documentation in the medical record maintained by the performing physician must support the following:</p> <ul style="list-style-type: none"> • The diagnosis of exudative senile macular degeneration has been firmly established by optical coherence tomography (OCT) or fluorescein angiography. • Actual dose administered in milligrams. <p>Utilization Guidelines It is expected that these services would be performed as indicated by current medical literature and/or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity Macular edema following retinal vein occlusion (RVO) should be reported as follows:</p>



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>diabetes mellitus with unspecified diabetic retinopathy with macular edema E09.321 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E09.331 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema E09.341 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E09.351 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema E10.311 Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema E10.321 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E10.331 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema E10.341 Type 1 diabetes mellitus with severe nonproliferative diabetic</p>	<ul style="list-style-type: none"> • Report macular edema with one of the following ICD-10-CM codes: H35.351; H35.352; H35.353; H35.359; or H35.81; AND • Report retinal vein occlusion (RVO) with one of the following ICD-10-CM codes: H34.811; H34.812; H34.813; H34.819; H34.831; H34.832; H34.833; or H34.839.
--	--	--	---



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>retinopathy with macular edema E10.351 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema E11.321 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E11.331 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema E11.341 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E11.351 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema E13.311 Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema E13.321 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E13.331 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p>	
--	--	--	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

			<p>E13.341 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E13.351 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>H34.811 Central retinal vein occlusion, right eye</p> <p>H34.812 Central retinal vein occlusion, left eye</p> <p>H34.813 Central retinal vein occlusion, bilateral</p> <p>H34.819 Central retinal vein occlusion, unspecified eye</p> <p>H34.831 Tributary (branch) retinal vein occlusion, right eye</p> <p>H34.832 Tributary (branch) retinal vein occlusion, left eye</p> <p>H34.833 Tributary (branch) retinal vein occlusion, bilateral</p> <p>H34.839 Tributary (branch) retinal vein occlusion, unspecified eye</p> <p>H35.32 Exudative age-related macular degeneration</p> <p>H35.351 Cystoid macular degeneration, right eye</p> <p>H35.352 Cystoid macular degeneration, left eye</p> <p>H35.353 Cystoid macular</p>	
--	--	--	--	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

			<p>degeneration, bilateral H35.359 Cystoid macular degeneration, unspecified eye H35.81 Retinal edema</p>	
<p>National Government Services www.ngsmedicare.com J6: Illinois, Minnesota, Wisconsin</p> <p>JK: Connecticut, Maine, Massachusetts, New Hampshire, New York, Rhode Island, Vermont</p> <p>A52451 L33394</p>	<p>67028 J2778</p>	<p>3 or 5</p>	<p>E08.311 Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema E08.321 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema E08.331 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema E08.341 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema E08.351 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema E08.359 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema E09.311 Drug or chemical induced</p>	<p>Utilization Guidelines: The recommended dosage for ranibizumab is 0.5mg, (10mg/ml) for neovascular (wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO) and 0.3mg (0.05mL) for diabetic macular edema. Please see the FDA label for frequency of treatment.</p> <p>Coding Guidelines:</p> <ul style="list-style-type: none"> • The administration for ranibizumab must be billed on the same claim as the drug, with CPT code 67028 (intravitreal injection of a pharmacologic agent). • The appropriate site modifier (RT, LT or 50) must be appended to CPT code 67028 to indicate if the service was performed unilaterally or bilaterally. Claims without a modifier will be returned to the provider unprocessed.



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>diabetes mellitus with unspecified diabetic retinopathy with macular edema</p> <p>E09.321 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E09.331 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E09.341 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E09.351 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E09.359 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema</p> <p>E10.311 Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema</p> <p>E10.321 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E10.331 Type 1 diabetes mellitus with</p>	
--	--	--	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

			<p>moderate nonproliferative diabetic retinopathy with macular edema E10.341 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E10.351 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema E10.359 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema E11.321 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E11.331 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema E11.341 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E11.351 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema E11.359 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema E13.311 Other specified diabetes</p>	
--	--	--	---	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>mellitus with unspecified diabetic retinopathy with macular edema E13.321 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema E13.331 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema E13.341 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema E13.351 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema E13.359 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema H34.811 Central retinal vein occlusion, right eye H34.812 Central retinal vein occlusion, left eye H34.813 Central retinal vein occlusion, bilateral H34.831 Tributary (branch) retinal vein occlusion, right eye H34.832 Tributary (branch) retinal vein occlusion, left eye</p>	
--	--	--	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

			<p>H34.833 Tributary (branch) retinal vein occlusion, bilateral</p> <p>H35.051 Retinal neovascularization, unspecified, right eye</p> <p>H35.052 Retinal neovascularization, unspecified, left eye</p> <p>H35.053 Retinal neovascularization, unspecified, bilateral</p> <p>H35.32 Exudative age-related macular degeneration</p> <p>H35.351 Cystoid macular degeneration, right eye</p> <p>H35.352 Cystoid macular degeneration, left eye</p> <p>H35.353 Cystoid macular degeneration, bilateral</p> <p>H35.81 Retinal edema</p>	
<p>Novitas Medicare Services www.novitas-solutions.com JH: Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas</p> <p>JL: Delaware, District of Columbia, Maryland, New Jersey, and Pennsylvania A53048</p>	67028 J2778	3 or 5	<p>ICD-10 Codes that Support Medical Necessity: N/A</p> <p>ICD-10 Codes that DO NOT Support Medical Necessity: N/A</p>	<ul style="list-style-type: none"> • OFC: For ranibizumab, providers should use the HCPCS code J2778 (Injection, ranibizumab, 0.1 mg), and bill for the proper number of units. For Part B, the actual number of mg. utilized should be noted in Item 19 of the CMS Form 1500 or its electronic equivalent. • ASC: For ranibizumab, providers should use the HCPCS code J2778 (Injection, ranibizumab, 0.1 mg), and bill for the proper number of units. For Part A, the correct number of units should be billed for the dose that is administered in field locator 46 of the UB-92 (CMS Form 1450) along



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

				with the revenue code 0636 (Drugs requiring specific identification-detailed coding) in field locator 42. For more information refer to CMS Articles: A52018, A49034 and A47797.
<p>Wisconsin Physician Service WPS www.wpsmedicare/index/shtml</p> <p>J5: Iowa, Kansas, Missouri, Nebraska</p> <p>J8: Indiana, Michigan</p> <p>L34741</p>	67028 J2778	3 or 5	<p>H35.81 Retinal edema AND one of the following:</p> <p>H34.811 Central retinal vein occlusion, right eye</p> <p>H34.812 Central retinal vein occlusion, left eye</p> <p>H34.813 Central retinal vein occlusion, bilateral</p> <p>H34.831 Tributary (branch) retinal vein occlusion, right eye</p> <p>H34.832 Tributary (branch) retinal vein occlusion, left eye</p> <p>H34.833 Tributary (branch) retinal vein occlusion, bilateral</p> <p>E08.321 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E08.331 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E08.341 Diabetes mellitus due to</p>	<p>Documentations Requirements The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures. The medical record must include the following information:</p> <ul style="list-style-type: none"> • A physician's order • The name of the drug or biological administered; • The route of administration; • The dosage (e.g., mgs, mcgs, cc's or IU's); • The duration of the administration- start and stop time must be documented for IV infusions. • When a portion of the drug or biological is discarded, the medical record must clearly document the amount administered and the amount wasted or discarded. <p>Utilization Guidelines Injections of drugs that are administered at an excessive frequency are not medically necessary. Frequency is considered excessive when services are performed more frequently than listed in the package insert or generally accepted by peers and the reason for additional services is not justified by documentation.</p>



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>underlying condition with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E08.351 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema</p> <p>E08.359 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema</p> <p>E09.321 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E09.331 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E09.341 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E09.351 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E09.359 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular</p>	<p>Proliferative diabetic retinopathy</p> <p>"wet" macular degeneration</p> <p>Retinal neovascularization-choroidal</p> <p>Diabetic macular edema Effective 08/10/12-FDA approval date</p> <p>Macular edema following Retinal vein occlusion (RVO): code macular edema and -Central retinal vein occlusion (CRVO) or -Venous tributary (branch) occlusion (BRVO).</p>
--	--	--	---



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>edema</p> <p>E10.321 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E10.331 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E10.341 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E10.351 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E10.359 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema</p> <p>E11.321 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E11.331 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E11.341 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E11.351 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E11.359 Type 2 diabetes mellitus with proliferative diabetic retinopathy</p>	
--	--	--	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

		<p>without macular edema</p> <p>E13.321 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema</p> <p>E13.331 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema</p> <p>E13.341 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema</p> <p>E13.351 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema</p> <p>E13.359 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema</p> <p>H34.831 Tributary (branch) retinal vein occlusion, right eye</p> <p>H34.832 Tributary (branch) retinal vein occlusion, left eye</p> <p>H34.833 Tributary (branch) retinal vein occlusion, bilateral</p> <p>H35.051 Retinal neovascularization, unspecified, right eye</p> <p>H35.052 Retinal neovascularization, unspecified, left eye</p> <p>H35.053 Retinal neovascularization,</p>	
--	--	---	--



Ranibizumab (Lucentis®) 0.1MG – Medicare Part B
Coding for Ophthalmic Use



Updated October 2015

Carriers Subject to Change – www.aao.org/coding

			unspecified, bilateral H35.32 Exudative age-related macular degeneration	
--	--	--	---	--